Synthekine — Valuation, Funding & Investors

Synthekine is a biotechnology company that applies protein engineering platforms to develop cytokine therapeutics for cancer and autoimmune disease, aiming to unlock the efficacy of cytokines while avoiding the toxicity that comes from their pleiotropic effects on the immune system. Its pipeline has included programs such as STK-009, SYNCAR-001 and SYNCAR-002, though those legacy programs are no longer in active development and are now available for partnering. The company was founded by Stanford professor and HHMI investigator K. Christopher Garcia, building on his research into cytokine receptor structures. Synthekine is based in Menlo Park, California, and was formed in 2019.

By the time it was hiring for its Phase 2 and 3 supply chain team, the clinical-stage biotech had raised $313 million from leading biotech investors.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Synthekine.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Synthekine availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Synthekine included.

Synthekine is a biotechnology company that applies protein engineering platforms to develop cytokine therapeutics for cancer and autoimmune disease, aiming to unlock the efficacy of cytokines while avoiding the toxicity that comes from their pleiotropic effects on the immune system.

Synthekine's total funding stands at $289.5M over 3 rounds.

Synthekine's most recent round was Series B, raising $107.5M in June 2021.

Synthekine's lead investors include Deerfield Management and Janus Henderson Investors.